Management of Pediatric Otitis Media

Ann McMahon Wicker, PharmD, BCPS; Brice Labruzzo Mohundro, PharmD

Disclosures

US Pharmacist 

In This Article

Traditional Pharmacologic Therapy

Symptom resolution and reduction of recurrence are the goals of treatment for AOM. Analgesics in addition to oral and topical antimicrobials are the mainstay of treatment. The use of antibacterial agents in children with uncomplicated AOM at the time of diagnosis has raised concerns regarding antibacterial resistance; however, AOM is the most common childhood infection for which antibacterial agents are prescribed in the U.S.[7] Antihistamines and decongestants may help relieve nasal allergies and congestion, but they have not been shown to improve healing or reduce the complications of AOM.[5] Dosing of analgesics and oral antibiotic agents in pediatric patients is based on weight (kg). Recommended dosing ranges are given in Table 2.

Since episodes of AOM frequently are associated with pain, the use of analgesics—especially during the first 24 hours of an episode—are strongly recommended by the AAP/AAFP guidelines. Treatment options to reduce the pain associated with otalgia include acetaminophen, ibuprofen, and antipyrine/benzocaine otic solution.[7] Antipyrine/benzocaine otic solution is a prescription product used for its local analgesic properties. After the solution is instilled into the ear canal, relief of ear pain occurs in approximately 30 minutes. This product is for otic use only, and it should not be used if the solution is brown or contains a precipitate. Disposal of the bottle is recommended 6 months after the dropper is placed in the solution.[12]

Treatment with an antibacterial agent is recommended for children younger than 6 months of age, children aged 6 months to 2 years with a certain diagnosis of AOM, and any child with moderate-to-severe otalgia or a fever of 102.2°F (39°C) or greater. Observation without antibacterial treatment may be considered for healthy children aged 6 months to 2 years with nonsevere illness and an uncertain diagnosis, as well as for children older than 2 years without severe symptoms or with an uncertain diagnosis for 48 to 72 hours; however, appropriate measures should be taken to allow caregiver–physician communication, reevaluation, and access to antibacterial therapy. A child being managed by observation would receive symptomatic treatment only. This recommendation is based on available evidence demonstrating that children who do not receive antibacterial treatment do well and experience no adverse events.[7]

High-dose amoxicillin is the recommended first-line treatment for children with AOM because of its efficacy and safety, low cost, palatability, and narrow microbiologic spectrum.[7] Because of the risk of highly resistant organisms, high-dose amoxicillin should not be used in children who received antibiotics in the previous 30 days, those with AOM and purulent conjunctivitis, or those receiving chronic prophylaxis with amoxicillin. This high-risk group should be given initial treatment with high-dose amoxicillin/clavulanate.

Cephalosporins are an alternative treatment for penicillin-allergic children as long as urticaria or anaphylaxis (type I hypersensitivity reaction) did not occur upon exposure to the penicillin. In children with a history of a penicillin-induced type I hypersensitivity reaction, clindamycin or the macrolide antibiotics azithromycin and clarithromycin may be used. Although high-dose amoxicillin is recommended as first-line therapy, data from pooled analyses did not find any particular antibiotic to have superior efficacy over other antibiotics. Antibiotics included in the comparison studies were penicillin, ampicillin, amoxicillin, amoxicillin/clavulanate, cefaclor, cefixime, ceftriaxone, azithromycin, and trimethoprim/sulfamethoxazole.[13]

The safety and efficacy of fluoroquinolones have been evaluated to determine the role of these agents in the treatment of OM. Studies have shown that fluoroquinolones may be an option for the treatment of multidrug-resistant AOM; these agents have been found to be clinically effective and to eradicate pathogens.[14] Safety is a primary concern with fluoroquinolone treatment in pediatric patients. Fluoroquinolones have a black box warning that their use is associated with an increased risk of tendonitis and tendon rupture in all age groups; however, bone or joint cartilage toxicity appears to occur in animals, without a profound effect in humans.[12,14]

The standard duration of treatment is 10 days, with a short course being 1 to 7 days.[7] Unfortunately, the most appropriate duration of antibiotic treatment has not been established, owing to limitations associated with the studies evaluating this; however, for children aged less than 6 years and all children with severe disease, the recommended treatment duration is 10 days. For children aged 6 years and older with mild-to-moderate AOM, a 5- to 7-day course of antibiotics is appropriate.[7] A 2000 Cochrane review of 30 trials concluded that, in otherwise healthy children without recurrent ear infections, a 5-day course of antibiotics was as effective as the 10-day course supported in the AAP/AAFP guidelines.[15]

Clinical improvement should be evident 48 to 72 hours after beginning initial AOM management. Children who do not respond to first-line therapy with high-dose amoxicillin should be given high-dose amoxicillin/clavulanate. Children who do not improve after initial treatment with high-dose amoxicillin/clavulanate should be switched to ceftriaxone (either intravenously or intramuscularly) daily for 3 consecutive days.[7]

Topical antibiotics are approved for use in children with tympanostomy tubes who are experiencing AOM and in children suffering from CSOM. The recommended treatment for patients with tympanostomy tubes who have AOM caused by susceptible stains of S aureus, S pneumoniae, H influenzae, M catarrhalis, or P aeruginosa is ciprofloxacin hydrochloride/dexamethasone otic suspension or ofloxacin otic solution. Ofloxacin otic solution may also be used to treat CSOM in children aged 12 years and older. In CSOM, ofloxacin otic solution is recommended for the treatment of susceptible strains of S aureus, P mirabilis, or P aeruginosa. Since ofloxacin otic solution is sterile, it can be used to treat otic infections even when the membrane is perforated, unlike the unsterile ciprofloxacin steroid combination.[11,12] Caregiver counseling regarding the proper administration of otic preparations is important (Table 3).

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....